Intravenous immunoglobulin for Guillain-Barré syndrome

Area of Science:

• Neurology
• Immunology

Background:

• Guillain-Barré syndrome is an acute, paralyzing, inflammatory peripheral nerve disease.
• Intravenous immunoglobulin (IVIG) is used for other autoimmune conditions.

Purpose of the Study:

• To determine the efficacy of IVIG in treating Guillain-Barré syndrome.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials comparing IVIG with plasma exchange or supportive care.
• Searched Cochrane Neuromuscular Disease Group register, MEDLINE, and EMBASE up to February 2003.

Main Results:

• IVIG showed no statistically significant difference in disability improvement compared to plasma exchange at four weeks.
• No significant differences were observed in time to walk unaided, mortality, or long-term walking ability.
• Combination therapies (IVIG with plasma exchange or immunoabsorption) did not show significant additional benefit over single treatments.

Conclusions:

• IVIG hastens recovery from Guillain-Barré syndrome comparably to plasma exchange, though direct placebo comparisons are lacking.
• Sequential IVIG after plasma exchange is not demonstrably superior to plasma exchange alone.
• Further randomized trials are required to assess IVIG's effectiveness in children, adults with mild disease, and those treated later than two weeks post-onset.